Clinical Trial Update: Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating three different dosages of NewGam for chronic inflammatory demyelinating polyneuropathy has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyneuropathy

Drugs mentioned

• NewGam (intravenous immunoglobulin)

Snippet

Sponsor: Octapharma | Conditions: Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy | Phase 3 | Status: COMPLETED | Results posted: 2021-02-16